Vasoactive intestinal peptide as a healing mediator in Crohn's disease

被引：36

作者：

Arranz, A. ^{[1
]}

Abad, C. ^{[3
]}

Juarranz, Y. ^{[1
]}

Leceta, J. ^{[1
]}

Martinez, C. ^{[2
]}

Gomariz, P. ^{[1
]}

机构：

[1] Univ Complutense, Fac Biol, Dept Cellular Biol, ES-28040 Madrid, Spain

[2] Univ Complutense, Fac Med, Dept Cellular Biol, ES-28040 Madrid, Spain

[3] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Canc Ctr, Mental Retardat Res Ctr,Semel Inst Neurosci, Los Angeles, CA 90095 USA

来源：

NEUROIMMUNOMODULATION | 2008年 / 15卷 / 01期

关键词：

vasoactive intestinal peptide; autoimmunity; Crohn's disease; inflammation;

D O I：

10.1159/000135623

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide (VIP/PACAP) system is considered as a paradigm for the use of a neuroendocrine-immune mediator in therapy. We review the role of VIP in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis as a murine model of Crohn's disease. VIP treatment led to the recovery of clinical factors, the amelioration of parameters related to the recruitment and traffic of cell populations, and the balance of inflammatory mediators derived from granulocytes, antigen-presenting cells and T lymphocytes including Th1, Th2 and Th17. Finally, the most recent data validate its therapeutic role through the modulation of TLR2 and 4 receptors. Copyright (C) 2008 S. Karger AG, Basel.

引用

页码：46 / 53

页数：8

共 28 条

[1] Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease [J].

Abad, C ;

Martinez, C ;

Juarranz, MG ;

Arranz, A ;

Leceta, J ;

Delgado, M ;

Gomariz, RP .

GASTROENTEROLOGY, 2003, 124 (04) :961-971

[2] Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: Focus on VIP and PACAP [J].

Abad, C ;

Gomariz, RP ;

Waschek, JA .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (02) :151-163

[3] CDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis:: Homeostatic role of VIP [J].

Abad, C ;

Juarranz, Y ;

Martinez, C ;

Arranz, A ;

Rosignoli, F ;

García-Gómez, M ;

Leceta, J ;

Gomariz, RP .

INFLAMMATORY BOWEL DISEASES, 2005, 11 (07) :674-684

[4] Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis [J].

Arranz, Alicia ;

Abad, Catalina ;

Juarranz, Yasmina ;

Torroba, Marta ;

Rosignoli, Florencia ;

Leceta, Javier ;

Perez Gomariz, Rosa ;

Martinez, Carmen .

VIP, PACAP, AND RELATED PEPTIDES: FROM GENE TO THERAPY, 2006, 1070 :129-134

[5] Origins and functions of B-1 cells with notes on the role of CD5 [J].

Berland, R ;

Wortis, HH .

ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :253-300

[6] Therapeutic impact of toll-like receptors on inflammatory bowel diseases: A multiple-edged sword [J].

Corio, Elke .

INFLAMMATORY BOWEL DISEASES, 2008, 14 (03) :411-421

[7] B cell developmental requirement for the Gαi2 gene [J].

Dalwadi, H ;

Wei, B ;

Schrage, M ;

Su, TT ;

Rawlings, DJ ;

Braun, J .

JOURNAL OF IMMUNOLOGY, 2003, 170 (04) :1707-1715

[8] The significance of vasoactive intestinal peptide in immunomodulation [J].

Delgado, M ;

Pozo, D ;

Ganea, D .

PHARMACOLOGICAL REVIEWS, 2004, 56 (02) :249-290

[9] Pivotal Advance: Vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages [J].

Foster, N. ;

Lea, S. R. ;

Preshaw, P. M. ;

Taylor, J. J. .

JOURNAL OF LEUKOCYTE BIOLOGY, 2007, 81 (04) :893-903

[10] An innate cell-mediated, murine ulcerative colitis-like syndrome in the absence of nuclear factor of activated T cells [J].

Gerth, AJ ;

Lin, L ;

Neurath, MF ;

Glimcher, LH ;

Peng, SL .

GASTROENTEROLOGY, 2004, 126 (04) :1115-1121

← 1 2 3 →